James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Joy Global Stock: So Bad It’s Good?

Joy Global stock may be a bargain after its price dropped on missed last-quarter estimates ... but only if the commodities market turns around.

Tesla Stock Owners May Not Like the Math of the Model 3

The math of the Model 3 may or may not make a great deal of sense for Tesla stock owners who are cheering the idea.

Netflix Stock: The Floodwaters Are Finally Starting to Rise on NFLX

Netflix stock is going to suffer a thousand cuts rather than one mighty blow as competitors like AAPL, AMZN edge into the market. But the result will be the same.

Why Ariad Pharmaceuticals, Inc. (ARIA), Dollar Tree, Inc. (DLTR) and Ambarella Inc (AMBA) Are 3 of Today’s Worst Stocks

Wednesday was nothing but misery for Ariad Pharmaceuticals (ARIA), Dollar Tree (DLTR) and Ambarella (AMBA) shareholders. Here's what you need to know.

Should You Buy Amgen Stock? 3 Pros, 3 Cons (AMGN)

If Amgen stock is going to move higher or lower in the foreseeable future, it could hinge on new AMGN drugs in the pipeline -- or the looming competition of biosimilars.